国家药品价格谈判政策对中国抗癌药物供应、使用和成本影响的新证据：中断时间序列研究

IF 2.7 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Risk Management and Healthcare Policy Pub Date : 2024-09-16 DOI:10.2147/rmhp.s473846

Xingyuan Gao, Man Yu, Yuyang Sun, Tiansi Zhang, Xin Li, Lingli Zhang, Changqing Wang

{"title":"国家药品价格谈判政策对中国抗癌药物供应、使用和成本影响的新证据：中断时间序列研究","authors":"Xingyuan Gao, Man Yu, Yuyang Sun, Tiansi Zhang, Xin Li, Lingli Zhang, Changqing Wang","doi":"10.2147/rmhp.s473846","DOIUrl":null,"url":null,"abstract":"Purpose: The increasing global burden of cancer has become a significant challenge for public health. The Chinese government introduced the National Drug Price Negotiation (NDPN) policy with the goal of lowering the prices of innovative drugs and enhancing their accessibility. This study aims to evaluate the impact of the 2021 NDPN policy on the availability, utilization, and cost of anticancer medicines in China. Methods: Data was gathered from 1519 hospitals between April 2021 and December 2022, with a focus on eight anticancer drugs affected by the 2021 NDPN policy. The availability, Defined Daily Doses (DDDs), and cost per Defined Daily Dose (DDDc) before and after the intervention were evaluated through interrupted time series analysis. Results: The NDPN policy resulted in a substantial 5.10% increase in the availability of anticancer drugs (p < 0.001). Utilization also experienced a significant surge, with an immediate increase of 11,254.36 DDDs (p < 0.001) and a monthly increase of 1208.28 DDDs (p < 0.001) following policy implementation. The DDDc decreased by US&dollar 111.00 (p < 0.001) immediately after the policy. Disparities in regional drug utilization were evident, with higher usage in the eastern region. Conclusion: The 2021 NDPN policy has notably enhanced the availability and utilization of anticancer medications in China while reducing their cost, in line with the policy’s objectives. However, continuous monitoring is essential to ensure sustained access and to tackle regional disparities in drug utilization. Keywords: anticancer medicines, national drug price negotiation, China, availability, utilization, cost, interrupted time series analysis ","PeriodicalId":56009,"journal":{"name":"Risk Management and Healthcare Policy","volume":"31 1","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study\",\"authors\":\"Xingyuan Gao, Man Yu, Yuyang Sun, Tiansi Zhang, Xin Li, Lingli Zhang, Changqing Wang\",\"doi\":\"10.2147/rmhp.s473846\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: The increasing global burden of cancer has become a significant challenge for public health. The Chinese government introduced the National Drug Price Negotiation (NDPN) policy with the goal of lowering the prices of innovative drugs and enhancing their accessibility. This study aims to evaluate the impact of the 2021 NDPN policy on the availability, utilization, and cost of anticancer medicines in China. Methods: Data was gathered from 1519 hospitals between April 2021 and December 2022, with a focus on eight anticancer drugs affected by the 2021 NDPN policy. The availability, Defined Daily Doses (DDDs), and cost per Defined Daily Dose (DDDc) before and after the intervention were evaluated through interrupted time series analysis. Results: The NDPN policy resulted in a substantial 5.10% increase in the availability of anticancer drugs (p < 0.001). Utilization also experienced a significant surge, with an immediate increase of 11,254.36 DDDs (p < 0.001) and a monthly increase of 1208.28 DDDs (p < 0.001) following policy implementation. The DDDc decreased by US&dollar 111.00 (p < 0.001) immediately after the policy. Disparities in regional drug utilization were evident, with higher usage in the eastern region. Conclusion: The 2021 NDPN policy has notably enhanced the availability and utilization of anticancer medications in China while reducing their cost, in line with the policy’s objectives. However, continuous monitoring is essential to ensure sustained access and to tackle regional disparities in drug utilization. Keywords: anticancer medicines, national drug price negotiation, China, availability, utilization, cost, interrupted time series analysis \",\"PeriodicalId\":56009,\"journal\":{\"name\":\"Risk Management and Healthcare Policy\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Risk Management and Healthcare Policy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/rmhp.s473846\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Risk Management and Healthcare Policy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/rmhp.s473846","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

摘要

目的：全球癌症负担日益加重，已成为公共卫生面临的重大挑战。中国政府出台了国家药品价格谈判（NDPN）政策，旨在降低创新药物的价格并提高其可及性。本研究旨在评估 2021 年国家药品价格谈判政策对中国抗癌药物供应、使用和成本的影响：方法：收集 2021 年 4 月至 2022 年 12 月期间 1519 家医院的数据，重点关注受 2021 年新药目录政策影响的八种抗癌药物。通过间断时间序列分析评估了干预前后的药品供应情况、每日定义剂量（DDDs）和每日定义剂量成本（DDDc）：结果：NDPN 政策使抗癌药物的供应量大幅增加了 5.10%（p < 0.001）。政策实施后，抗癌药物的使用量也出现了大幅增长，立即增加了 11,254.36DDs (p <0.001)，每月增加 1208.28DDDs(p <0.001)。政策实施后，DDDc 立即减少了 111.00 美元（p <0.001）。地区用药差异明显，东部地区用药量较高：2021 年新药目录政策显著提高了中国抗癌药物的可获得性和使用率，同时降低了抗癌药物的成本，符合政策目标。关键词：抗癌药；国家药品价格谈判；中国；供应；使用；成本；间断时间序列分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study

Purpose: The increasing global burden of cancer has become a significant challenge for public health. The Chinese government introduced the National Drug Price Negotiation (NDPN) policy with the goal of lowering the prices of innovative drugs and enhancing their accessibility. This study aims to evaluate the impact of the 2021 NDPN policy on the availability, utilization, and cost of anticancer medicines in China.
Methods: Data was gathered from 1519 hospitals between April 2021 and December 2022, with a focus on eight anticancer drugs affected by the 2021 NDPN policy. The availability, Defined Daily Doses (DDDs), and cost per Defined Daily Dose (DDDc) before and after the intervention were evaluated through interrupted time series analysis.
Results: The NDPN policy resulted in a substantial 5.10% increase in the availability of anticancer drugs (p < 0.001). Utilization also experienced a significant surge, with an immediate increase of 11,254.36 DDDs (p < 0.001) and a monthly increase of 1208.28 DDDs (p < 0.001) following policy implementation. The DDDc decreased by US&dollar 111.00 (p < 0.001) immediately after the policy. Disparities in regional drug utilization were evident, with higher usage in the eastern region.
Conclusion: The 2021 NDPN policy has notably enhanced the availability and utilization of anticancer medications in China while reducing their cost, in line with the policy’s objectives. However, continuous monitoring is essential to ensure sustained access and to tackle regional disparities in drug utilization.

Keywords: anticancer medicines, national drug price negotiation, China, availability, utilization, cost, interrupted time series analysis

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Risk Management and Healthcare Policy Medicine-Public Health, Environmental and Occupational Health

CiteScore

6.20

自引率

2.90%

发文量

242

审稿时长

16 weeks

期刊介绍： Risk Management and Healthcare Policy is an international, peer-reviewed, open access journal focusing on all aspects of public health, policy and preventative measures to promote good health and improve morbidity and mortality in the population. Specific topics covered in the journal include: Public and community health Policy and law Preventative and predictive healthcare Risk and hazard management Epidemiology, detection and screening Lifestyle and diet modification Vaccination and disease transmission/modification programs Health and safety and occupational health Healthcare services provision Health literacy and education Advertising and promotion of health issues Health economic evaluations and resource management Risk Management and Healthcare Policy focuses on human interventional and observational research. The journal welcomes submitted papers covering original research, clinical and epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, and extended reports. Case reports will only be considered if they make a valuable and original contribution to the literature. The journal does not accept study protocols, animal-based or cell line-based studies.